22 April 2005 Final Programme - The British Society for Rheumatology

OP54 RHEUMATOID FACTOR IS AN INDEPENDENT RISK FACTOR FOR ISCHAEMIC HEART DISEASE
IN MEN.
C.J. Edwards 1,2 , H.E. Syddall 2 , P. Goswami 1 , R. Goswami 1 , E.M. Dennison 2 , N.K. Arden 1,2 , C. Cooper 2
1
Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, United
Kingdom; 2 Medical Research Council Epidemiology Resource Centre, University of Southampton,
Southampton, United Kingdom
OP55 INCREASED ARTERIAL STIFFNESS IN PATIENTS WITH TAKAYASU'S ARTERITIS.
W.F. Ng 1 , R. Schiff 2 , F. Dockery 2 , K.A. Davies 3 , C. Rajkumar 3 , J.C. Mason 1
1
Rheumatology, Eric Bywaters Centre, Hammersmith Hospital, London, United Kingdom; 2 Elderly Care,
Hammersmith Hospital, London, United Kingdom; 3 Medicine, Brighton and Sussex Medical School,
Brighton, United Kingdom
OP56 A ROLE FOR PROTEASE-ACTIVATED RECEPTOR-2 IN THROMBIN-MEDIATED CYTOPROTECTION
OF VASCULAR ENDOTHELIUM.
E.A. Lidington 1 , R. Steinberg 1 , A. Kinderlerer 1 , C. Landis 1 , M. Ohba 2 , A. Samarel 3 , D.O. Haskard 1 , J.C.
Mason 1
1
Cardiovascular Medicine Unit, Eric Bywaters Centre, Imperial College, London, United Kingdom; 2 Institute
of Molecular Oncology, Showa University, Tokyo, Jordan; 3 The Cardiovascular Institute, Loyola University,
Chicago, United States
OP57 ANOMALOUS NKG2D EXPRESSION ON CD4+CD28- T-CELLS IN WEGENER'S
GRANULOMATOSIS.
A. Mueller 1 , D. Capraru 1 , K. Holl-Ulrich 2 , E. Csernok 1 , J. Voswinkel 1 , W.L. Gross 1 , P. Lamprecht 1
1
Department of Rheumatology, University Hospital of SH, Campus Luebeck, Luebeck, Germany; 2 Institute
of Pathology, University Hospital of SH, Campus Luebeck, Luebeck, Germany
OP58 EUROPEAN MEDICINES AGENCY (EMEA) CONSENSUS ON THE CLASSIFICATION OF THE PRIMA-
RY SYSTEMIC VASCULITIDES (PSV) FOR EPIDEMIOLOGICAL STUDIES.
S.E. Lane 1 , R.A. Watts 1 , D.G.I. Scott 2
On Behalf of EMEA Vasculitis Group; 1 Rheumatology, Ipswich Hospital, Ipswich, Suffolk, United Kingdom;
2
Rheumatology, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom
OP59 PRIMARY SYSTEMIC VASCULITIS - UNCHANGED INCIDENCE OVER 15 YEARS.
R.A. Watts 1 , S.E. Lane 1 , J. Mooney 2 , D.G.I. Scott 2
1
Rheumatology Department, Ipswich Hospital, Ipswich, Suffolk, United Kingdom; 2 Rheumatology
Department, Norfolk & Norwich University Hospital, Norwich, Norfolk, United Kingdom
OP60 INTERFERON-ALPHA TREATMENT IN REFRACTORY CHURG-STRAUSS SYNDROME: FIRST RESULTS
OF A PHASE II PROSPECTIVE OPEN LABEL STUDY.
C. Metzler, W.L. Gross, B. Hellmich
Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
Therapeutics II (OP61 – OP68) Hall 1
OP61 MORTALITY AMONG RA PATIENTS RECEIVING ANTI-TNFα THERAPY IN THE UNITED KINGDOM:
RESULTS FROM THE BSR BIOLOGICS REGISTER.
K. Watson, K. Hyrich, A. Silman, D. Symmons
The BSR Biologics Register; ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom
OP62 EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) IN EUROPEAN CLINICAL PRACTICE:
THE REACT TRIAL.
G.R. Burmester 1 , P. Wordsworth 2 , X. Mariette 3 , I. Monteagudo Sáez 4 , J.W.J. Bijlsma 5 , D.G. Webber 6 ,
H. Kupper 6
1
Universitätsklinikum Charité, Berlin, Germany; 2 University of Oxford, Oxford, United Kingdom; 3 Centre
Hospitalier de Bicêtre, Bicêtre, France; 4 H.G.U. Gregorio Marañón, Madrid, Spain; 5 University Medical
Center Utrecht, Utrecht, Netherlands; 6 Abbott GmbH & Co. KG, Ludwigshafen, Germany
32